Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

NCT02745561 is registered in ClinicalTrials.gov with Hangzhou Cancer Hospital as lead sponsor.

NCT NCT02745561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02745561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
Lead sponsor
Hangzhou Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2016
Completion date
December 31, 2018
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endostatin, esophageal cancer